Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixion 2.0: FX06 in Acute Respiratory Distress Syndrome
2021-005059-35Phase 2Active
- Sponsor
- F4 Pharma
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing FX06 with Placebo (2 arms). Primary endpoint: Time to initial unassisted breathing by day 28. Started Dec 2021; status: active.
02
Drugs
FX06
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2021-005059-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005059-35.